The monoclonal antibodies, especially omalizumab, are new drugs that are showing great efficacy in the treatment of standard drug resistance allergic asthma. The drug omalizumab was recently approved by the Food and Drug Administration (FDA) and is currently on the market for patients who are resistant to standard therapy. Numerous studies have shown significant improvement of patients that have severe allergic asthma with resistance to standard therapy, with only minimal side effects.